Table 3.
Cerebrospinal fluid biomarker data in all groups
| NfL (pg/ml) Median (IQR) |
t-taua (pg/ml) Median (IQR) |
p-taub (pg/ml) Median (IQR) |
Aβ42c (pg/ml) Median (IQR) |
t-tau/p-tau Median (IQR) |
NfL/p-tau Median (IQR) |
14-3-3 (positive) | ||
|---|---|---|---|---|---|---|---|---|
| Prion disease | Typical (n = 82) | 15,000 (9254–24,425) | 7048 (3549–10,550) | 60 (47–75) | 646 (420–811) | 121.60 (66.18–194.90) | 257.89 (177.94–402.00) | 82/82 |
| Atypical (n = 59) | 9139 (5234–17,000) | 1546 (933–2221) | 44 (34–63) | 527 (372–771) | 33.57 (21.43–54.91) | 215.98 (125.26–425.00) | 21/59 | |
| Total prion disease (n = 141) | 12,300 (7160–22,650) | 3103 (1803–8555) | 51 (40–71) | 620 (399–780) | 66.94 (33.57–152.67) | 247.29 (156.02–404.71) | 103/141 | |
| AD | Typical (n = 36) | 1933 (1515–2788) | 572 (424–817) | 80 (67–105) | 363 (277–437) | 7.09 (6.11–7.80) | 23.55 (18.48–30.27) | 0/36 |
| Atypical (n = 37) | 2521 (1662–3330) | 1115 (772–1631) | 123 (102–153) | 352 (257–508) | 8.90 (7.85–10.32) | 17.39 (12.86–28.85) | 4/37 | |
| Total AD (n = 73) | 2033 (1592–3067) | 822 (565–1186) | 106 (74–143) | 358 (268–465) | 7.84 (6.71–9.72) | 20.30 (14.85–29.77) | 4/73 | |
| DLB | Typical (n = 24) | 1857 (1398–2682) | 268 (125–395) | 42 (34–54) | 647 (334–912) | 5.63 (4.76–7.18) | 41.85 (30.39–61.69) | 0/22 |
| Atypical (n = 11) | 4207 (1633–29,500) | 713 (230–1374) | 51 (31–112) | 360 (179–559) | 7.43 (5.10–19.91) | 88.91 (19.10–573.97) | 3/10 | |
| Total DLB (n = 35) | 2171 (1414–4007) | 275 (160–438) | 42 (33–61) | 476 (303–722) | 6.20 (4.89–8.18) | 42.34 (28.68–94.20) | 3/32 | |
| FTLD | Typical (n = 35) | 3191 (1910–4963) | 217 (154–378) | 38 (27–53) | 711 (570–928) | 6.12 (4.40–7.91) | 78.00 (40.13–158.08) | 0/31 |
| Atypical (n = 9) | 6785 (3785–12,500) | 341 (198–849) | 45 (31–52) | 708 (372–877) | 7.80 (6.02–10.42) | 153.54 (72.90–364.83) | 1/9 | |
| Total FTLD (n = 44) | 3628 (2308–6647) | 245 (173–407) | 41 (28–53) | 709 (546–920) | 6.52 (4.76–9.02) | 86.06 (43.11–197.90) | 1/40 | |
| bvFTD (n = 19) | 3729 (1910–11,900) | 204 (150–380) | 35 (26–44) | 717 (519–922) | 6.52 (4.69–7.80) | 153.54 (41.24–304.65) | 1/17 | |
| PPA (n = 6) | 5626 (2768–8173) | 393 (177–637) | 47 (34–62) | 928 (744–1214) | 7.78 (5.83–10.71) | 109.11 (63.12–177.75) | 0/6 | |
| Tauopathies (CBS + PSP) (n = 19) | 2733 (2459–3940) | 244 (177–373) | 45 (28–57) | 619 (452–785) | 6.54 (4.30–8.13) | 60.73 (40.13–138.74) | 0/17 | |
| Control subjects | Total (n = 30) | 1167 (805–1543) | 164 (136–255) | 38 (30–46) | 815 (642–1045) | 5.43 (4.06–6.20) | 33.00 2(20.22–44.26) | NA |
Abbreviations: Aβ42 β-Amyloid 42, AD Alzheimer’s disease, bvFTD Behavioral variant of frontotemporal dementia, CBS Corticobasal syndrome; DLB Dementia with Lewy bodies, FTLD Frontotemporal lobar degeneration, NA Not available, NfL Neurofilament light chain protein, PPA Primary progressive aphasia, PSP Progressive supranuclear palsy, p-tau Phosphorylated tau protein, t-tau Total tau protein
aPrion disease vs. control subjects (p < 0.001); prion disease vs. each ND group (p < 0.001); AD vs. control subjects (p < 0.001); AD vs. each ND group (p < 0.001)
bAD vs. prion disease (p < 0.001); prion disease vs. FTLD (p < 0.001); prion disease vs. bvFTD (p < 0.001); AD vs. FTLD (p < 0.001); AD vs. bvFTD or PPA or tauopathies (p < 0.001)
cPrion disease vs. AD (p < 0.001); FTLD vs. DLB (p = 0.018); DLB vs. PPA (p = 0.004); AD vs. FTLD (p < 0.001); AD vs. bvFTD or PPA or tauopathies (p < 0.001); AD vs. DLB (p = 0.024)